| Business Summary | | IMPATH
Inc.
focuses
on
the
clinical
application
of
advanced
technologies
in
the
community-based
hospital
environment
to
enable
clinicians
to
make
better
treatment
decisions
for
their
cancer
patients.
The
Company
expanded
its
focus
to
harness
the
information
it
was
generating
from
performing
analyses
on
thousands
of
cancer
specimens
annually,
and
to
broaden
the
value
applications
of
that
biological
information.
The
Company
has
also
completed
multiple
strategic
acquisitions
that
have
provided
technologies;
complementary
cancer
information
including
longitudinal
treatment
and
outcomes
data;
pharmacoeconomic
analytical
capabilities,
and
a
tissue
and
serology
archive
of
well-characterized,
fully
documented
cancer
specimens.
IMPATH
serves
the
oncology
community
through
three
operating
divisions:
Physician
Services,
IMPATH
Predictive
Oncology
(formerly
BioPharmaceutical/Genomics
Services
(Biopharma)
and
Information
Services. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | IMPATH
provides
patient-specific
cancer
diagnostic
and
prognostic
information,
with
a
particular
expertise
in
difficult
to
diagnose
tumors,
prognostic
profiles
in
breast
and
other
cancers,
and
lymphoma/leukemia
analysis.
For
the
six
months
ended
6/30/01,
revenues
rose
40%
to
$89.2
million.
Earnings
rose
42%
to
$8.3
million.
Results
reflect
an
increase
in
the
case
volumes
of
physician
services,
higher
revenue
realization
per
case,
and
the
Company's
streamlining
efforts. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Anu Saad, Ph.D., 44 Chairman,
CEO | $521K | -- | Richard Adelson, 35 Pres,
COO | 347K | $1.3M | David Cammarata, 37 CFO | 238K | 1.3M | James Douglass, Ph.D., 51 CIO | 283K | 194K | Richard Rosenzweig, 34 Gen.
Counsel, Sec. | -- | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|